The webinar will feature presentations by Key Opinion Leaders (KOLs) Giovanni Frisoni, MD, of University of Geneva and the Memory Clinic at Geneva University Hospital, and Kaj Blennow, MD, PhD of University of Gothenburg and Sahlgrenska University Hospital.

Drs. Frisoni and Blennow will discuss improved techniques and agents in development to detect and monitor the disease at earlier stages in order to deliver therapeutic vaccines to delay or even prevent the onset of irreversible clinical symptoms. The availability of biomarkers measurable by brain imaging and in biofluids as clinical endpoints will enable a Precision Medicine approach for agents treating pre-symptomatic patients.

AC Immune management will discuss the Company’s integrated Precision Medicine approach for Alzheimer’s disease leveraging its cutting-edge PET-tracer programs and two Alzheimer’s disease vaccines in clinical development targeting amyloid beta (ACI-24.060) and Tau (ACI-35.030).

A live question and answer session will follow the formal presentations.